Abrocitinib Studied as Second-Line Biologic in Atopic Dermatitis

Abrocitinib shows consistent efficacy and safety in patients with moderate-to-severe atopic dermatitis, whether or not they've already been treated with a biologic, researchers report.

Related Keywords

Winston Salem ,North Carolina ,United States ,Tennessee ,Canada ,Wake Forest University ,Vanderbilt University ,Lindsayc Strowd ,Melinda Gooderham ,Jamil Miller ,Skin Centre For Dermatology ,Vanderbilt University Medical Center ,Drug Administration ,Society For Investigative Dermatology ,Investigative Dermatology ,Bio Experienced With ,Global Assessment ,Eczema Area ,Severity Index ,Expand Treatment ,Medscape Medical ,Wake Forest University School ,Dermatitis ,Atopic Dermatitis ,Jak Stat ,Ak Stat Signaling Pathway ,Ak Stat Cytokine Receptors ,Biologic Therapy ,Eczema ,Riga ,